Rockwell Medical Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Rockwell Medical Reports Third Quarter 2015 Results
November 10, 2015 7:42 AM EST
Oppenheimer analyst Ling Wang reiterated an Outperform rating and $26 price target on Rockwell Medical Technologies (NASDAQ: RMTI) following the company Q3 updated. The analyst notes the company singed a signed a supply contract with one of the top four dialysis providers for Triferic, although... More
November 10, 2015 6:29 AM EST
Brean Capital analyst Jonathan Aschoff reiterated a Sell rating and $4 price target on Rockwell Medical Technologies (NASDAQ: RMTI) noting Triferic sales were not material enough to even disclose.
Aschoff commented, "Rockwell launched Triferic in the US in September but has not yet generated sales material enough to report separately as Triferic revenue. Rockwell admitted the sales are minimal, and prices are currently being negotiated with individual dialysis providers. We expect... More
November 9, 2015 4:58 PM EST
Rockwell Medical Technologies (NASDAQ: RMTI) reported Q3 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.93 million.
For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.
...
More
